Tazarotene Gel
NDC Package 73473-310-10

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Tazarotene gel is tazarotene is used to treat psoriasis or acne. This formulation utilizes a gel delivery system. Marketed by Solaris Pharma Corporation, this product is identified by NDC 73473-310 and is authorized under FDA application ANDA213644.

Identification & Billing

NDC Package Code
73473-310-10
Package Description
1 TUBE in 1 CARTON / 100 g in 1 TUBE
Product Code
73473-310
11-Digit Billing Format
73473031010
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Tazarotene
Non-Proprietary Name
Tazarotene
Substance Name
Tazarotene
Dosage Form
Gel - A semisolid3 dosage form that contains a gelling agent to provide stiffness to a solution or a colloidal dispersion.4 A gel may contain suspended particles.
Administration Route
Cutaneous - Administration to the skin.
Active Ingredient(s)
TAZAROTENE 1 mg/g
Pharmacologic Class
Usage Information
Tazarotene is used to treat psoriasis or acne. It is a retinoid product related to Vitamin A. It works by affecting the growth of skin cells. The foam and lotion forms of this medication are only approved for use on acne.

Regulatory & Marketing

Labeler Name
Solaris Pharma Corporation
Product Type
Human Prescription Drug
FDA Application #
ANDA213644
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-03-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (73473-310). Click a package code to view its specific billing and regulatory data.

73473-310-30
1 TUBE in 1 CARTON / 30 g in 1 TUBE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73473-310-10 identifies a specific commercial package of 1 tube in 1 carton / 100 g in 1 tube of Tazarotene, a human prescription drug labeled by Solaris Pharma Corporation. This gel is formulated for cutaneous use and contains tazarotene as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Solaris Pharma Corporation on January 03, 2025. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Tazarotene is used to treat psoriasis or acne. It is a retinoid product related to Vitamin A. It works by affecting the growth of skin cells. The foam and lotion forms of this medication are only approved for use on acne.

How is this Solaris Pharma Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73473031010. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
73473-310-10
11-Digit CMS (5-4-2)
73473-0310-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.